Author:
Sinisalo Juha,Vlachopoulou Efthymia,Marchesani Marja,Nokelainen Johanna,Mäyränpää Mikko I.,Lappalainen Jani,Paakkanen Riitta,Wennerström Annika,Salli Krista,Niemi Heikki J.,Männistö Satu,Salo Perttu,Junttila Juhani,Eskola Markku,Nikus Kjell,Arstila T. Petteri,Perola Markus,Huikuri Heikki,Karhunen Pekka J.,Kovanen Petri T.,Palotie Aarno,Havulinna Aki S.,Lluis-Ganella Carla,Marrugat Jaume,Elosua Roberto,Salomaa Veikko,Nieminen Markku S.,Lokki Marja-Liisa
Abstract
Background—
The
HLA-DRB1*01
allele of the human leukocyte antigen has been associated with acute coronary syndrome. Genome-wide association studies have revealed associations with human leukocyte antigen and non–human leukocyte antigen genes of 3 major histocompatibility complex gene classes but not at allelic level.
Methods and Results—
We conducted a large-scale genetic analysis on a case–control cohort comprising 5376 acute coronary syndrome cases and 4852 unrelated controls from 4 populations of 2 European countries. We analyzed the risk candidate allele of
HLA-DRB1*01
by genomic real-time polymerase chain reaction together with high-density single nucleotide polymorphisms of the major histocompatibility complex to precisely identify risk loci for acute coronary syndrome with effective clinical implications. We found a risk haplotype for the disease containing single nucleotide polymorphisms from
BTNL2
and
HLA-DRA
genes and the
HLA-DRB1*01
allele. The association of the haplotype appeared in 3 of the 4 populations, and the direction of the effect was consistent in the fourth. Coronary samples from subjects homozygous for the disease-associated haplotype showed higher
BTNL2
mRNA levels (
r
=0.760;
P
<0.00001).We localized, with immunofluorescence staining, BTNL2 in CD68-positive macrophages of the coronary artery plaques. In homozygous cases, BTNL2 blocking, in T-cell stimulation assays, enhanced CD4
+
FOXP3
+
regulatory T cell proliferation significantly (blocking versus nonblocking;
P
<0.05).
Conclusions—
In cases with the risk haplotype for acute coronary syndrome, these results suggest involvement of enhanced immune reactions. BTNL2 may have an inhibitory effect on FOXP3
+
T cell proliferation, especially in patients homozygous for the risk alleles.
Clinical Trial Registration—
https://www.clinicaltrials.gov
; Unique Identifier: NCT00417534.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Genetics(clinical),Cardiology and Cardiovascular Medicine,Genetics